Cissus for Weight and Metabolic Outcomes: The Trials

This is the strange part of the Cissus file. The plant's traditional claim is fracture healing, where the evidence is old, weak and positive. The plant's commercial claim is weight loss — and there the evidence is modern, randomised, placebo-controlled, and compromised in a different way. There really are double-blind trials reporting weight, body-fat, lipid and glucose improvements. They are also small, short, clustered around a handful of investigators and one proprietary extract, and — the point that matters most — several of them administered a multi-ingredient product, which means a positive result cannot be credited to Cissus quadrangularis without checking what was in the capsule.

That last problem is not a technicality. It is the difference between "this plant reduces body fat" and "a formula containing this plant plus another plant reduces body fat", and the supplement market prints the first while citing the second.


Table of Contents

  1. What Is Claimed
  2. The Trials, Read as Designs
  3. What Was Actually Administered
  4. Investigator Clustering and Sponsorship
  5. Proposed Mechanisms
  6. The Cortisol-Blocker Story
  7. Glucose and Lipids: Benefit and Hazard in One Property
  8. Eight Weeks and What It Cannot Tell You
  9. What a Trial That Settled This Would Need
  10. Against Interventions That Do Have Evidence
  11. Evidence Ledger
  12. Numbers This Page Refuses to Give
  13. Key Research Papers
  14. Connections
  15. Featured Videos

What Is Claimed

The marketing bundle usually contains five separate assertions:

  1. Body weight and body fat fall on a Cissus extract, with or without diet change.
  2. Metabolic-syndrome markers improve — total and low-density lipoprotein (LDL) cholesterol, triglycerides, fasting glucose.
  3. Appetite is reduced, usually attributed to serotonergic or hormonal effects.
  4. Fat absorption is reduced by pancreatic lipase inhibition.
  5. Cortisol is "blocked", preventing stress-related abdominal fat gain.

Claims 1 and 2 have randomised human trials behind them, and this page takes them seriously. Claims 3 and 4 rest on enzyme assays and animal work. Claim 5 has essentially nothing and is discussed separately because it is the most confidently asserted of the five.

The Trials, Read as Designs

Evidence tier: randomised, placebo-controlled, small, short, clustered, a proprietary extract, and in several cases multi-ingredient.

The core body of work comes from a group publishing out of Cameroon in Lipids in Health and Disease in the mid-to-late 2000s, associated with J. E. Oben and colleagues, using proprietary standardised Cissus extract material.

  1. Oben and colleagues, 2006 — The use of a Cissus quadrangularis formulation in the management of weight loss and metabolic syndrome. Randomised, double-blind and placebo-controlled in 123 overweight and obese adults over eight weeks, with reported reductions in body weight and central obesity and improvements in lipid and glucose measures. Note the word "formulation" in the title. The abstract does not list what the capsule contained, so this page does not assume it was a single ingredient.
  2. Oben and colleagues, 2007 — a study contrasting a proprietary single-plant Cissus extract (300 mg a day) with a proprietary multi-ingredient formulation containing it (1,028 mg a day) in obesity and obesity-induced oxidative stress. The double-blind, placebo-controlled part enrolled 168 overweight and obese people, of whom 153 completed it. Both the single extract and the formula were reported to bring significant reductions in weight, body fat, total and LDL cholesterol, triglycerides and fasting blood glucose over the study period. This is one of three designs in the file with a single-plant arm, alongside the 2008 and 2019 trials below.
  3. Oben and colleagues, 2008 — The use of a Cissus quadrangularis / Irvingia gabonensis combination in the management of weight loss: a double-blind placebo-controlled study. Three arms of 24 people each (72 in all): Cissus alone, Cissus plus Irvingia gabonensis, and placebo, over ten weeks. The Cissus-only arm showed significant reductions on all six measures (body weight, body fat, waist size, total cholesterol, LDL cholesterol and fasting blood glucose) compared with placebo, and the combination arm was reported as the largest effect. The combination is the headline result, and Irvingia gabonensis is a separate plant with its own weight-loss literature from the same research group. A larger effect in a two-plant arm is evidence about two plants.
  4. Nash, Oben and colleagues, 2019 — the single-plant extract alone. An 8-week double-blind, placebo-controlled pilot trial by the same Cameroon group, in 67 overweight people asked to keep their normal diet and exercise: 35 took 300 mg a day of the single-plant extract and 32 took 300 mg of corn starch. Body fat was measured two ways. On Cissus it fell 8.9% by bioelectrical impedance and 12.8% by DEXA (dual-energy X-ray absorptiometry) scan; on placebo it fell 1.05% by impedance and did not change on DEXA. Compared with placebo, the Cissus group also had significant decreases in waist and hip circumference, systolic and diastolic blood pressure, total cholesterol, triglycerides, fasting blood glucose and leptin, and increases in high-density lipoprotein (HDL) cholesterol and adiponectin. The paper's conflict-of-interest statement says the study was funded by the University of Yaoundé 1, where two of its authors work.
  5. Smaller pilot and open-label studies using various extracts, sometimes alongside dietary advice, reporting modest weight and lipid changes. Several lacked blinding. These add volume rather than strength.
  6. Sawangjit and colleagues, 2017 — systematic review and meta-analysis of randomised trials of Cissus quadrangularis in clinical use, in Phytotherapy Research. It included 9 trials with 1,108 patients across indications. For weight it could pool only combination products, which outperformed placebo: body weight −5.19 kg (95% confidence interval −8.82 to −1.55), LDL cholesterol −14.43 mg/dl, triglycerides −37.50 mg/dl, total cholesterol −50.50 mg/dl and fasting blood sugar −10.39 mg/dl. By GRADE (Grading of Recommendations Assessment, Development and Evaluation) it rated the evidence from low quality (bone fractures) to high quality (hemorrhoids, body-weight reduction), and it concluded that high-quality studies are still needed. This is the appropriate reference for anyone who wants one citation rather than five.

What Was Actually Administered

This is the decisive methodological point on the page, and it generalises well beyond Cissus.

When a trial administers a formula and reports a benefit, the benefit belongs to the formula. Crediting it to one named constituent requires either a single-ingredient arm, or a design that isolates the component. In the Cissus weight-loss literature:

What this page therefore claims: that randomised trials of Cissus-containing materials have reported weight and metabolic improvements; that three designs (2007, 2008 and 2019) included a single-plant arm, each reporting significant reductions with it, all from the same research programme; that the largest effects, and the only pooled weight result, come from combination products; and that the composition of the tested material is found in the methods rather than the abstract.

Investigator Clustering and Sponsorship

Reporting funding and authorship relationships is not an accusation; it is part of describing the evidence, and it is disclosed in the papers themselves.

Proposed Mechanisms

Four mechanisms are offered. All are hypotheses about why an effect might exist rather than evidence that it does.

The Cortisol-Blocker Story

Cissus is sold across the fitness market as a "cortisol blocker" that prevents stress-driven abdominal fat gain. This deserves its own section because it is asserted with more confidence than anything else on the label and supported by less.

What exists: the plant contains phytosterols and, by the industry's own standardisation, a fraction marketed as "ketosterones", and 3-ketosteroids are structurally in the same broad chemical territory as steroid hormones. What does not exist: any adequate human study showing that oral Cissus lowers cortisol, and any study linking such a change to fat distribution. Structural resemblance is not pharmacology.

Two further problems sit underneath the claim. First, the ketosterone assay is not standardised between laboratories, so the marketed fraction is not a defined quantity. Second, "blocking cortisol" is not obviously desirable even if it were achievable — cortisol is required for glucose regulation, blood pressure and the response to physical stress, and an agent that genuinely suppressed it would carry the safety profile of a corticosteroid antagonist, not of a fat burner. A mechanism that would be dangerous if true, and is asserted without evidence, is worth naming as marketing rather than pharmacology.

Glucose and Lipids: Benefit and Hazard in One Property

Several trials and animal studies report lower fasting glucose with Cissus. Taken as a benefit claim this is modest and unconfirmed. Taken as a safety observation it is the most practically important finding on this page — and it is the same property described twice.

If the glucose-lowering effect is real, it is additive with the drugs people already take for that purpose: metformin, sulfonylureas such as glipizide, glyburide and glimepiride, meglitinides, and insulin. Someone whose medication was titrated before they started the supplement can drift into more frequent hypoglycaemia, and the symptoms — shakiness, sweating, confusion — are easily misread as a side effect of the herb rather than an interaction with the prescription. An added glucose-lowering effect on top of these medicines raises the risk of low blood sugar (hypoglycaemia), whose signs include shakiness, sweating and confusion. This is expanded in Cissus: Dose, Formulations and Safety.

The reported lipid changes carry a milder version of the same logic for someone on a statin or an antihypertensive: no interaction is documented, but an unmeasured variable has been added to a titrated regimen. See Lipid Panel and Hemoglobin A1C.

Eight Weeks and What It Cannot Tell You

The trials ran roughly eight to ten weeks. Three things follow, and they are not minor.

  1. Nothing about weight maintenance. Almost any intervention produces weight loss over eight weeks; the entire difficulty of obesity treatment is the twelve to twenty-four month horizon, where most losses are regained. A short trial cannot address the actual clinical question. See Obesity.
  2. Nothing about safety over the period of real use. People take supplements for years. Eight weeks cannot detect a slowly accumulating harm, and with a plant carrying meaningful oxalate that is not an abstract concern — see Kidney Stones.
  3. Nothing about uncommon adverse events. A hundred participants split across arms cannot detect a harm occurring in one user in a few hundred.

What a Trial That Settled This Would Need

Naming the study that would resolve the question is more useful than hedging, and obesity pharmacotherapy has a mature, well-specified trial methodology to borrow from.

  1. A single-ingredient, assayed intervention with a documented certificate of analysis, so the trial tests the plant and not a mixture.
  2. Randomised, double-blind, placebo-controlled, with a matched placebo and allocation concealment.
  3. Twelve months minimum, which is the standard duration for a weight-loss agent, with a maintenance phase.
  4. Percentage body-weight change as the primary endpoint, plus the proportion of participants achieving five and ten percent loss — the thresholds regulators and clinicians use.
  5. Body composition by DXA or equivalent, not bioimpedance, so a fat-versus-lean claim can be made honestly.
  6. Standardised background diet and activity, or at minimum measured and reported, since unmeasured lifestyle change is the commonest confounder in supplement trials.
  7. Prespecified metabolic secondary endpoints: fasting glucose, hemoglobin A1c (HbA1c), a full lipid panel, blood pressure, waist circumference.
  8. Adequate power for a modest effect, meaning several hundred participants across multiple independent sites.
  9. Pre-registration, intention-to-treat analysis and an independent statistician.

None of this is beyond a botanical. It is how orlistat, and later the glucagon-like peptide-1 (GLP-1) agonists, were assessed. Twenty years after the first positive Cissus trial, no study of this shape has been published.

Against Interventions That Do Have Evidence

The point of naming comparators is to show that the question is answerable, not to sell an alternative.

Evidence Ledger

  1. Best supported: that randomised placebo-controlled trials of Cissus-containing materials have reported short-term weight, body-fat, lipid and fasting-glucose improvements. Tier: modern randomised human evidence, small, short, clustered, and in several cases multi-ingredient.
  2. Materially weaker than it looks: attribution of those results to Cissus quadrangularis alone. Tier: partly confounded — three designs (2007, 2008 and 2019) included a single-plant arm and each reported significant reductions with it, but the most-cited headline result is the two-plant arm, and all three come from one research programme.
  3. Mechanistic, not clinical: lipase, amylase and glucosidase inhibition. Tier: in vitro, with no human pharmacokinetics to bridge the gap.
  4. Asserted without evidence: cortisol blocking. Tier: marketing — and a mechanism that would carry corticosteroid-antagonist risks if it were real.
  5. Outside view: a 2020 meta-analysis of 54 placebo-controlled trials of herbal medicines for weight loss listed Cissus quadrangularis among the herbs, each tested in three or fewer trials, for which statistically and clinically significant weight loss compared with placebo had been reported (clinically significant meaning a difference of at least 2.5 kg). The authors wrote that these findings "should be interpreted cautiously because of the small number of studies, generally poor methodological quality, and poor reporting of the herbal medicine interventions", and concluded: "There is currently insufficient evidence to recommend any of the herbal medicines for weight loss included in the present review."
  6. Absent: anything about weight maintenance beyond ten weeks, and anything about safety over years of use.
  7. The most robust finding on this page is a safety observation, not a benefit: the reported glucose-lowering effect, which matters most to people taking diabetes medication.

Numbers This Page Refuses to Give

Key Research Papers

Entries ending in a PubMed PMID link to the verified record of that paper; entries ending in “Search PubMed” are topic searches, not single papers. Citations involving a second plant or a formulation are labelled as such at the citation.

  1. Systematic review and meta-analysis — the appropriate single citation. Sawangjit R, Puttarak P, Saokaew S, Chaiyakunapruk N. Efficacy and safety of Cissus quadrangularis L. in clinical use: a systematic review and meta-analysis of randomised controlled trials. Phytotherapy Research, 2017;31(4):555-567. PubMed PMID: 28165166
  2. The 2006 trial — note "formulation" in the title; the abstract does not give the composition of the tested material. Oben J, Kuate D, Agbor G, Momo C, Talla X. The use of a Cissus quadrangularis formulation in the management of weight loss and metabolic syndrome. Lipids in Health and Disease, 2006;5:24. PubMed PMID: 16948861
  3. Single plant versus formulation, side by side — one of three designs with a single-plant arm. Oben JE, Enyegue DM, Fomekong GI, Soukontoua YB, Agbor GA. The effect of Cissus quadrangularis (CQR-300) and a Cissus formulation (CORE) on obesity and obesity-induced oxidative stress. Lipids in Health and Disease, 2007;6:4. PubMed PMID: 17274828
  4. Two-plant combination — the headline arm is not Cissus alone. Oben JE, Ngondi JL, Momo CN, Agbor GA, Sobgui CS. The use of a Cissus quadrangularis/Irvingia gabonensis combination in the management of weight loss: a double-blind placebo-controlled study. Lipids in Health and Disease, 2008;7:12. PubMed PMID: 18377661
  5. The single-plant extract alone against placebo. Nash R, Azantsa B, Kuate D, Singh H, Oben J. The use of a stem and leaf aqueous extract of Cissus quadrangularis (CQR-300) to reduce body fat and other components of metabolic syndrome in overweight participants. Journal of Alternative and Complementary Medicine, 2019;25(1):98-106. PubMed PMID: 29912570
  6. Different plant — cited to show where part of the combination effect may live. This is African mango, not Cissus, studied in mouse fat cells in the laboratory. Oben JE, Ngondi JL, Blum K. Inhibition of Irvingia gabonensis seed extract (OB131) on adipogenesis as mediated via down regulation of the PPARgamma and leptin genes and up-regulation of the adiponectin gene. Lipids in Health and Disease, 2008;7:44. PubMed PMID: 19014517
  7. Narrative review. Stohs SJ, Ray SD. A review and evaluation of the efficacy and safety of Cissus quadrangularis extracts. Phytotherapy Research, 2013;27(8):1107-14. PubMed PMID: 22976133
  8. Independent group, waist and hip compared with baseline; fat-cell result in the laboratory. Chatree S, Sitticharoon C, Maikaew P, Pongwattanapakin K, Keadkraichaiwat I, Churintaraphan M, Sripong C, Sririwichitchai R, Tapechum S. Cissus Quadrangularis enhances UCP1 mRNA, indicative of white adipocyte browning and decreases central obesity in humans in a randomized trial. Scientific Reports, 2021;11(1):2008. PubMed PMID: 33479386
  9. Herbal weight-loss meta-analysis. Maunder A, Bessell E, Lauche R, Adams J, Sainsbury A, Fuller NR. Effectiveness of herbal medicines for weight loss: a systematic review and meta-analysis of randomized controlled trials. Diabetes, Obesity and Metabolism, 2020;22(6):891-903. PubMed PMID: 31984610
  10. Enzyme-inhibition mechanism — in vitro only. Reports of pancreatic lipase, alpha-amylase and alpha-glucosidase inhibition by Cissus quadrangularis extracts. Confirm journals and years from the records; these are assays, not doses. — Search PubMed
  11. Antihyperglycaemic and antihyperlipidaemic animal work. Rodent studies reporting lower glucose and improved lipid profiles with Cissus quadrangularis extracts — the preclinical basis of the safety point in this page rather than of a treatment claim. — Search PubMed
  12. Safety assessment of a standardised extract. Subchronic toxicity and genotoxicity evaluation of a standardised Cissus quadrangularis extract, published in the toxicology literature around 2011. Metadata should be confirmed from the record. — Search PubMed
  13. How weight-loss agents are actually assessed. Regulatory-standard endpoints in obesity pharmacotherapy trials — twelve-month duration, percentage weight change, five and ten percent responder thresholds. The bar a supplement claim is implicitly measuring itself against. — Search PubMed
  14. Why short trials mislead. Long-term weight-regain literature after successful short-term loss. — Search PubMed

PubMed Topic Searches

  1. Cissus quadrangularis, obesity, randomised trials
  2. Cissus quadrangularis and metabolic syndrome
  3. Cissus quadrangularis and blood glucose
  4. Cissus quadrangularis and cortisol — see how little returns.
  5. Irvingia gabonensis and weight loss — the other plant in the combination.

External Resources

  1. NCCIH — how botanical evidence is graded.
  2. NIDDK — the US institute for diabetes, digestive and kidney disease.
  3. PubMed — the primary literature.

Connections


Back to Table of Contents